Chickasaw Strategic Pointe, LLC, a subsidiary of Chickasaw Nation Industries, has been awarded a $22 million contract to deliver pharmacovigilance systems implementation and IT lifecycle support for the FDA’s Adverse Event Reporting System (FAERS) II program.
“CNI is proud to partner with the FDA to help with the detection and reporting of adverse events,” said Eduardo Marques, President and COO of CNI’s Division of Civilian Services. “Our team of pharmacovigilance and HL7 data standards experts and technical professionals are truly dedicated to supporting this mission critical program.”
READ MORE: Chickasaw Nation Industries Recognizes its Employees Supporting CDC
The four-year IDIQ (indefinite delivery/indefinite quantity) contract begins the first week of April.
Chickasaw Nation Industries, Inc. (CNI) is a federally chartered corporation wholly owned by the Chickasaw Nation. Recently, the CNI team, in partnership with the FDA, was awarded a FedHealthIT Innovation Award.
READ MORE: David Nimmo, Chickasaw Nation Industries: A High-Powered CEO With a ‘Servant’s Heart’
To offer an overview of CNI’s evolution and broad impact: In less than 20 years, CNI has gone from a fledgling business awaiting 8(a) status approval to a giant conglomerate with 24 subsidiaries and employing 1,850 people.
CNI specializes in government contracting, manufacturing and fluid filtration for clients that include the U.S. military, government agencies, the Ford Motor Company, and heavyweights of the energy industry.
